RAGE Re‐Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions
Journal of Cachexia, Sarcopenia and Muscle · 2026-06 · 17 (3)
DOI: 10.1002/jcsm.70302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 09.05.2026. Verfasst von Sara Chiappalupi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Receptor for Advanced Glycation End Products, Cachexia, Neoplasms, Muscular Atrophy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AIRC, Consorzio Interuniversitario per le Biotecnologie (CIB), Fondazione Veronesi fellowship.
Abstract (Originalsprache)
Background
Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end‐products (RAGE) is expressed by several cell types and sustains the inflammatory response in acute and chronic diseases. Total ablation of RAGE ( Ager −/− mice) translates into restrained CC and increased survival in tumour‐bearing mice. RAGE, which is not expressed in adult healthy myofibres, is re‐expressed in atrophying myofibres in cancer conditions. However, the specific contribution of muscular RAGE to CC was unknown.
Methods
Using an HSA/Cre‐ loxP system, we generated a tamoxifen‐inducible conditional Ager mKO mouse model in which RAGE is selectively ablated in myofibres. Tamoxifen‐treated Ager mKO , Ager flox and Ager −/− mice were subcutaneously injected with Lewis lung carcinoma (LLC) cells, and body changes and survival were monitored until 25 dpi, when histological, molecular and proteomic analyses were performed in tumour‐bearing and control mice. Muscle samples of pre‐cachectic and cachectic pancreatic cancer patients were analysed to validate the results.
Results
Compared with LLC‐ Ager flox mice, LLC‐ Ager mKO mice showed reduced (7.5% [ p = 0.004] vs. 15.1% [ p < 0.0001]) body weight loss, no significant reduction of hind‐limb muscle mass and strength and myofibre cross‐sectional areas, increased survival (69.2% vs. 42.9% mice alive at 25 dpi) and restrained muscle and serum pro‐inflammatory factors. Mechanistically, Ager mKO muscles resist cancer‐induced atrophy by maintaining an active Akt‐GSK‐3β‐PGC‐1α pathway, and increasing the synthesis of myosin heavy chain (MyHC)‐I and ‐IIa (71.8% [ p = 0.008] and 73.9% [ p = 0.002] increase, respectively) along with a 76.3% ( p = 0.008) increase in hybrid MyHC‐I/IIa myofibres. Distinct proteomic signatures characterize muscles of tumour‐bearing mice in dependence on RAGE expression, supporting a protective effect of RAGE ablation in muscles. LLC/ Ager mKO muscles showed increased amounts of several enzymes involved in glycolysis and glucose catabolism, typical of Warburg metabolism. Noteworthy, muscles of pre‐cachectic and cachectic cancer patients showed ~3‐fold increase ( p < 0.05) in RAGE amounts and reduced Akt‐GSK‐3β‐PGC‐1α pathway, compared with healthy control subjects.
Conclusions
Our data provide evidence that RAGE engagement at myofibre level drives loss of body and muscle weights and inflammation in cancer conditions. RAGE ablation in muscles confers resistance to CC through myofibre remodeling and glycolytic reprogramming. On the clinical side, the overexpression of RAGE is an early event in muscles of cancer patients, suggesting a role for RAGE in the onset of the cachectic syndrome. Thus, the molecular targeting of RAGE might be useful to counteract cachexia and prolong survival in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Interuniversity Institute of Myology (IIM), Perugia, Italy.
- Consorzio Interuniversitario Biotecnologie (CIB), Trieste, Italy.
- Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
- Institute for Molecular and Translational Cardiology (IMTC), IRCCS Policlinico San Donato, Milan, Italy.
- Department of Medicine, NYU Grossman School of Medicine, New York, USA.
ORCID-Profile: Guglielmo Sorci
Förderung
- AIRC
- Consorzio Interuniversitario per le Biotecnologie (CIB)
- Fondazione Veronesi fellowship
- Artificial Intelligence Research Center
Zitieren
APA
Chiappalupi, S., Gentili, G., Salvadori, L., Paiella, M., Manfredi, M., Borrini, V. F., Mangar, K., Schmidt, A. M., Muscaritoli, M., Riuzzi, F., & Sorci, G. (2026). RAGE Re‐Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions. Journal of Cachexia, Sarcopenia and Muscle, 17(3). https://doi.org/10.1002/jcsm.70302
Vancouver
Chiappalupi S, Gentili G, Salvadori L, Paiella M, Manfredi M, Borrini VF, et al. RAGE Re‐Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(3). doi:10.1002/jcsm.70302
BibTeX
@article{Chiappalupi2026,
author = {Chiappalupi, Sara and Gentili, Giulia and Salvadori, Laura and Paiella, Martina and Manfredi, Marcello and Borrini, Vittoria Federica and Mangar, Kaamashri and Schmidt, Ann Marie and Muscaritoli, Maurizio and Riuzzi, Francesca and Sorci, Guglielmo},
title = {RAGE Re‐Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
volume = {17},
number = {3},
doi = {10.1002/jcsm.70302}
}
EUVIMED